Skip to main content
Text us Contact us
Natural Medicine

Psilocybin for Depression: What the Research Shows

Two positive Phase 3 trials, an FDA filing and relief that can last months from one or two sessions: what the research shows and what Colorado offers now.

In this article
  1. The short answer
  2. The early trials
  3. How it compares with an antidepressant
  4. The Phase 3 trials
  5. A mixed result from Germany
  6. How long it lasts
  7. Why these studies are hard to read
  8. Where psilocybin fits
  9. What this means in Colorado
  10. The bottom line

On November 9, 2026, Compass Pathways finished filing its application asking the FDA to approve psilocybin for treatment-resistant depression. If the agency says yes, it will be the first time a classic psychedelic has been approved as a medicine.

Depression is the condition psilocybin has been studied for longest and in the most people, and the record is now substantial: two positive Phase 3 trials, a head-to-head comparison with an antidepressant and follow-up out to a year. It also has limits the headlines skip. Below is what each major trial found, what is encouraging and what isn’t settled.

The short answer

Psilocybin with psychological support relieves depression in controlled trials, and for some people the relief lasts. Two Phase 3 trials with more than 800 people found a benefit in people who had been depressed for years and had not been helped by several medications. Improvement showed up within a day of the session. In smaller studies, the benefit from one or two sessions held for six months to a year.

On symptoms it does about as well as antidepressants, by a different route. In the one head-to-head trial, two psilocybin sessions matched six weeks of a daily antidepressant on the main measure and came out ahead on functioning, sense of meaning and connectedness. That is one or two supported sessions in place of a medication taken every day.

It has limits. Average effects in the large trials were smaller than the early studies suggested, a carefully blinded German trial missed its main goal and not everyone responds.

It is not FDA-approved, and it is legal and regulated in Colorado. As of November 18, 2026, the FDA application is under review. It covers treatment-resistant depression only, and no price has been set. Colorado’s licensed program is open now to adults 21 and older.

The early trials

Johns Hopkins, 2021. The Hopkins trial in JAMA Psychiatry enrolled 27 adults with major depression. They were randomly assigned to start right away or wait eight weeks. Each received two psilocybin sessions with about 11 hours of supportive psychotherapy around them. Four weeks after the second session, 71% of those who completed treatment had improved by at least half and 54% were in remission. In a 12-month follow-up, 75% still met the response threshold and 58% were in remission. Those are striking numbers from a small study with no placebo. Everyone knew they had received psilocybin, and a waiting group is a weak comparison.

COMP360 Phase 2b, 2022. The first large trial, published in the New England Journal of Medicine, enrolled 233 people at 22 sites in 10 countries. All had treatment-resistant depression, meaning two to four medications had already failed in the current episode. Each received a single dose of 25 mg, 10 mg or 1 mg of synthetic psilocybin with psychological support, and the 1 mg dose served as the control. Three weeks later the 25 mg group had improved by 6.6 points more than the 1 mg group on the Montgomery-Åsberg Depression Rating Scale (MADRS), a 60-point clinician rating. In that group 37% had improved by at least half and 29% were in remission. The improvement was at its largest the day after the session. By 12 weeks, 20% still met the response threshold. Adverse events were common, and suicidal thoughts or behavior occurred in all three dose groups.

Usona Institute, 2023. A trial in JAMA at 11 US sites gave 104 adults with major depression a single 25 mg dose of psilocybin or a dose of niacin, a vitamin that causes flushing and was used as an active placebo. Six weeks later the psilocybin group scored 12.3 points lower on the MADRS than the niacin group. There were no serious adverse events, though side effects overall were more frequent with psilocybin.

How it compares with an antidepressant

Only one trial has tested psilocybin directly against a standard antidepressant. Researchers at Imperial College London assigned 59 people with moderate to severe depression to one of two arms. One received two 25 mg psilocybin sessions three weeks apart plus a daily placebo. The other received two very low doses of psilocybin plus daily escitalopram. Both received the same psychological support.

After six weeks the two groups did not differ significantly on the trial’s main measure, a self-rated depression scale. Put plainly, two sessions did as well as six weeks of daily medication. On secondary measures psilocybin looked better: 57% were in remission compared with 28% on escitalopram. The authors cautioned that those secondary comparisons were not corrected for the number of tests they ran, so they suggest a difference without establishing one. Both findings are true, and quoting only one of them misrepresents the trial.

A six-month follow-up found that both groups had held their improvement in depressive symptoms. People in the psilocybin group reported greater gains in social functioning, sense of meaning and connectedness.

In March 2026 a meta-analysis in JAMA Psychiatry took up the same question at scale. Its starting point is that people in psychedelic trials nearly always know what they received, while people in antidepressant trials usually don’t. So it compared eight trials of psychedelic therapy (psilocybin and related drugs) with 16 antidepressant trials in which participants also knew they were getting the real medication. Under those equal conditions the difference between the two was 0.3 points on a standard depression scale, which is no meaningful difference.

That finding takes some air out of the early headlines, because the large gaps over placebo in earlier trials owed a good deal to study design. It also says something useful. Under fair conditions psychedelic therapy holds its own against the standard medications, with one or two sessions in place of a daily pill. One of the authors described it as a valuable additional option.

The Phase 3 trials

Compass Pathways ran two Phase 3 trials of COMP360, its synthetic psilocybin, in treatment-resistant depression. The people enrolled had been depressed for a long time. Their current episodes had lasted more than three years on average. COMP005 was the first Phase 3 trial of a classic psychedelic to report a positive result.

COMP005 gave 258 people either a single 25 mg dose or a placebo. At six weeks the psilocybin group had improved by 3.6 points more on the MADRS.

COMP006 gave 581 people two doses three weeks apart, at 25 mg, 10 mg or 1 mg. At six weeks the 25 mg group had improved by 3.8 points more than the 1 mg group.

Both results were statistically significant, and in COMP005 the improvement was measurable from the day after dosing. They are reported in a conference abstract and in company announcements. The average differences are a little more than half the size of the Phase 2b result, which was measured at three weeks. By the company’s figures, 25% of the 25 mg group in COMP005 and 39% in COMP006 had improved by at least a quarter at six weeks, and among those people the benefit held on average through week 26. The threshold matters here: earlier trials counted a response as an improvement of at least half.

Most side effects occurred on the dosing day and cleared within a day. The most common were headache, nausea, visual hallucinations and anxiety. Serious adverse events were reported in 2.3% of participants or fewer, and the abstract reports no meaningful imbalance in suicidal thinking between groups.

When this post was written, the full Phase 3 results had not appeared in a peer-reviewed journal. The FDA application was filed under a priority program that targets a decision within one to two months. Approval would cover this one product, and the DEA would still have to reschedule it before it could be prescribed.

Who it would be for. The application is for treatment-resistant depression: major depression that at least two medications have failed to help. It is not for depression in general. The Phase 3 trials were narrower still. They excluded people with bipolar disorder, a psychotic disorder or borderline personality disorder. They also excluded anyone with ongoing PTSD, OCD or anorexia and anyone hospitalized for psychiatric reasons in the past year. So the evidence describes people whose depression was close to their only diagnosis. The company has said it expects a broad label for treatment-resistant depression. What the FDA will write isn’t known yet.

What it would cost. No price has been set. The company has told investors it plans to price per dose and is aiming for a yearly cost near that of an existing approved drug for treatment-resistant depression, which it puts at $50,000 to $65,000. It expects most people to receive two to four doses a year. That works out to roughly $17,000 to $22,000 a dose, and in November 2026 executives said they believe they can price higher. Insurance coverage is still being negotiated.

A mixed result from Germany

The German EPIsoDE trial, published in JAMA Psychiatry in March 2026, is among the most carefully blinded psilocybin trials so far. It enrolled 144 adults with treatment-resistant depression at two centers. Participants, clinicians and raters were all kept unaware of assignments, and the placebo was nicotinamide, a form of vitamin B3. Everyone had two sessions six weeks apart, in different sequences of 25 mg, 5 mg and placebo, so every participant received the full dose at least once.

The trial’s main question was how many people had improved by at least half six weeks after the first session. With 25 mg it was 17%, which was not significantly more than with placebo. The trial did not meet its primary endpoint.

The secondary results point the other way. One week after the session, far more people in the 25 mg group had responded. At six weeks their average scores were 4.6 points lower than the placebo group’s on the Hamilton depression scale. By 12 weeks, when everyone had received 25 mg at least once, all groups had improved by an average of 7.5 points and no longer differed.

Suicidal thoughts on dosing days were more common with 25 mg (4%, compared with 1% to 2% in the other groups). There were two serious adverse reactions: a marked rise in blood pressure and a perceptual disturbance that persisted.

The authors called the trial inconclusive overall, reported a significant antidepressant effect on the secondary measures and asked for larger studies. With careful blinding and a strict definition of response, the effect was clear at one week and hard to separate from placebo at six.

How long it lasts

Durability is the main attraction of a treatment given once or twice. The Hopkins participants held their gains for a year. That was 24 people, some of whom started other treatment along the way. The Imperial groups held theirs for six months. In Phase 3, the people who responded held that response on average through six months.

The limits are real too. In the Phase 2b trial only one in five people in the 25 mg group still met the response threshold at 12 weeks, and the Phase 3 responders were a minority.

A fair reading is that some people get a lasting benefit from one or two sessions and others don’t. Nobody can yet predict who. One clue comes up across several trials, EPIsoDE included: people who reported a stronger emotional or mystical-type experience during the session tended to improve more. We cover that in our post on the mystical experience, and the biology behind it in how psilocybin works.

Why these studies are hard to read

Blinding barely works. People almost always know whether they received a full dose of psilocybin. Expectation can lift results in the psilocybin group, and disappointment can hold them down in the control group. Both widen the gap.

The early trials were small. Hopkins analyzed 24 people and Imperial 59. Small trials tend to overstate effects, and the larger trials that followed found smaller ones.

Participants are carefully screened. These trials excluded people with a history of psychosis or mania, people with active suicidal intent and people with serious medical conditions. The Phase 3 trials also excluded borderline personality disorder and ongoing PTSD or OCD. Depression often comes with other diagnoses, and for those people the trials have little to say.

Most participants stopped their antidepressants first. In the Phase 2b, Usona and EPIsoDE trials, people came off medication before dosing. One small open-label study kept 19 people on their SSRI and still saw improvement, but it had no comparison group. Stopping medication carries its own risks, and a trial result is not a reason to do it.

The support varied. Hopkins provided about 11 hours of psychotherapy and Imperial about 20. In every one of these trials psilocybin came with preparation and follow-up, so nobody knows how much of the benefit belongs to the drug alone.

The same cautions apply to the research on psilocybin for anxiety, psilocybin for OCD and psilocybin for alcohol and addiction.

Where psilocybin fits

Cognitive behavioral therapy, behavioral activation and antidepressant medication each have decades of controlled trials behind them. If you haven’t had a full course of one, that is usually where we’d start. See depression treatment at FRTC and how behavioral activation works.

“Treatment-resistant” deserves a second look before anyone accepts the label. Often it means earlier treatment was too brief, the wrong fit or missing a piece such as a structured therapy. Our page on treatment-resistant depression describes what a reassessment covers. When depression comes with intense emotion or suicidal thinking, DBT for depression addresses that directly.

Psilocybin is a reasonable thing to ask about when:

  • medication helped only partly, or its side effects cost more than it gave you
  • you’ve done solid therapy and still feel stuck
  • you’d prefer one or two supported sessions to a medication you take every day
  • what you most want back is a sense of meaning and connection, which is where psilocybin did best against an antidepressant

It doesn’t have to be one or the other. In every trial psilocybin was added to psychological support, and many people keep their therapy going around a session.

What this means in Colorado

In Colorado you don’t have to wait for the FDA. Under the Natural Medicine Health Act, adults 21 and older can have a psilocybin session with a licensed facilitator at a licensed healing center now. You don’t need a diagnosis, a referral or a history of failed medications.

The shape is the one the trials used: screening, preparation, a supported session and integration afterward. Some things differ, and it’s worth being precise about them. The trials used synthetic psilocybin given by medical research teams, with standardized symptom ratings and many hours of psychotherapy. Colorado’s program uses a regulated natural psilocybin product, facilitators are not prescribers and a session on its own is not a treatment plan for depression.

The trials never tested psilocybin alone either. They paired it with psychological support, and that pairing is what we build: preparation and integration with licensed clinicians, in coordination with your therapist and prescriber.

If the FDA approves COMP360, that will be a separate medical route for one product. It would be open to a narrower group than Colorado’s program and is expected to cost far more than a facilitated session, though insurance may cover part of it. Colorado’s program doesn’t depend on it.

What that means in practice:

You don’t have to stop an antidepressant. Most trial participants came off theirs, and one small study found people improved while staying on an SSRI. We don’t ask anyone to taper an SSRI or SNRI for a session. Any medication change is a decision for you and your prescriber, and facilitators can’t direct one. We cover both sides of the question in psilocybin and SSRIs. Lithium and MAOIs rule a session out.

Screening asks about your whole history. A history of mania or psychosis rules a session out, and so do active suicidal thoughts with a plan. Suicidal thoughts occurred in some trial participants after dosing, which is one reason screening asks about them directly. See how screening works and our post on psilocybin and suicidal ideation.

One session or two is an open question. Hopkins, Imperial and COMP006 used two sessions. COMP005 and the Usona trial used one. No trial has compared the two directly. We describe the two-session format in what a psilocybin journey series involves.

Plan for integration. If you have a therapist or a prescriber, keep them informed, and treat integration as part of the work.

The bottom line

Psilocybin has more trial evidence for depression than for any other condition. Two Phase 3 trials found a benefit in people whose depression had lasted years, and the FDA is reviewing an application. In the fairest comparisons, one or two sessions did about as well as a daily antidepressant, and people who responded tended to hold that response for months.

It isn’t a cure and it doesn’t work for everyone. Average effects were modest, one careful trial missed its endpoint and the FDA product, if approved, will be for a narrow group at a high price.

In Colorado the option is open now, with screening, preparation and integration built in. If depression has outlasted what you’ve tried, or you want a different route than daily medication, it’s worth a conversation.


Considering natural medicine for depression? Get in touch or book a free 15-minute consultation. We’ll talk through your history, including whether therapy or a medication review should come first. You may also want to read is psilocybin therapy right for you, how psilocybin works or learn about our natural medicine services.

This post is educational and is not medical advice. Psilocybin sessions under Colorado’s Natural Medicine Health Act are not a substitute for treatment of depression. Don’t stop or change a psychiatric medication without talking to your prescriber. If you’re thinking about suicide, call or text 988.

At FRTC in Denver

Psilocybin-assisted therapy at FRTC

State-licensed facilitators, under Colorado’s Natural Medicine Health Act. Each journey has preparation before and integration after.

Send a messageBook a free call

← Back to all articles

Ask about natural medicine services

Tell us how to reach you and we’ll get back to you — usually within one business day.

You’re asking about

Natural Medicine Services

We usually reply within one business day. What you write here is confidential — but please don’t include clinical details you wouldn’t want in an email, and if you’re in crisis, call or text 988.

Interested in a different program? Use our full contact form →